Jun 16, 2024, 17:20
Yvonne Diaz: EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer
Yvonne Diaz, Co-founder of Oncogene Cancer Research, shared a post on X:
“Great to see that EU Medicines Agency has approved Alecensa (alectinib) for early stage stage ALK+ lung cancer following the success of the ALINA clinical trial.
This highlights the need for biomarker testing across all stage non-small cell lung cancer patients.”
Additional information.
Source: Yvonne Diaz/X